Bionuu offers High Dose Vitamin C infusions to help cancer patients. The Riordan intravenous vitamin C (IVC) protocol has been used safely for many years. The Riordan clinic has treated hundreds of cancer patients using the Riordan protocol and the Riordan Clinic Research Institute (RCRI) has been researching the potential of intravenous vitamin C therapy for over thirty years.
Summary of reasons for using intravenous ascorbate infusions (IVC) to treat cancer:
- Plasma ascorbate (vitamin C) concentrations in high range can be safely achieved with IVC infusions.
- At high concentrations, ascorbate is toxic to cancer cells in vitro and is able to inhibit angiogenesis in vitro and in vivo.
- Vitamin C can accumulate in tumors, with significant tumor growth inhibition seen in guinea pigs at intra-tumor concentrations of 1 mM or higher.
- Published case studies report anti-cancer efficacy, improved patient well-being, and decreases in markers of inflammation and tumor growth.
- Phase I clinical studies indicate that IVC can be administered safely with relatively few adverse effects.
- Candidates include those who have failed standard treatment regimens; those seeking to improve the effectiveness of their standard cancer therapy; those seeking to decrease the severity and carcinogenicity of side effects from standard cancer therapy; those attempting to prolong their remission with health-enhancing strategies; those declining standard treatment, yet wishing to pursue primary, alternative treatment.
- There are some medical exclusions and/or relative contraindications. Lab work and review of medical records is needed prior to starting the protocol.
- The doses vary and they are related with the level of Vitamin C in the blood that the patients achieve after the administration of the IVC. The protocol is usually administered twice a week, in rare cases three times a week.